Exagen Diagnostics Names James McClintic CEO

Oct 26, 2005, 01:00 ET from Exagen Diagnostics, Inc.

    ALBUQUERQUE, N.M., Oct. 26 /PRNewswire/ -- Exagen Diagnostics, Inc., which
 develops and commercializes genomic marker-based in vitro diagnostic (IVD)
 kits for disease prognosis and prediction of treatment response, today
 announced that James McClintic has joined the company as president and CEO.
 McClintic succeeds Exagen founding CEO Waneta Tuttle, who will turn her
 attention to Southwest Medical Ventures, the venture development company she
 owns. Tuttle will continue as a member of the Exagen board of directors.
     "Exagen has reached an important milestone and is now poised to begin
 commercializing its diagnostic tests on a global scale," said Tuttle. "With
 his depth of knowledge in the clinical laboratory arena and a proven track
 record of growing start-up companies, Jim McClintic is the ideal person to
 lead Exagen through its next phase of development."
     Before joining Exagen, McClintic served as president and CEO of Esoterix,
 Inc., which performs laboratory services involving diagnosis and monitoring of
 serious diseases and conditions including asthma, bleeding disorders, cancer,
 diabetes and infectious diseases. During his six-year tenure there, McClintic
 grew annual revenues from $50 million to $120 million and orchestrated the
 sale of Esoterix to LabCorp, Inc. for $150 million. Previously, McClintic was
 regional president of eastern operations for Corning Clinical Labs, now Quest.
 He also held positions as president of SciCor, Inc., vice president of sales
 for the eastern zone of Bristol-Myers Squibb, and various sales and marketing
 management positions with E.R. Squibb & Sons, Inc.
     "Exagen's approach to genomic diagnostic tests is truly state of the art
 and represents an exciting opportunity to put high science in the hands of
 physicians who will use it to give patients a significantly better quality of
 life," said McClintic. "I welcome the opportunity to devise the company's
 strategic direction for the next phase of growth and ultimately, to elevate
 Exagen's place in the market."
     Exagen's products address the rapidly growing molecular diagnostics
 segment of the $22 billion in vitro diagnostics market. Next year, the company
 will launch its Key2(TM) Breast Cancer Prognostic Tests, the first and only
 reagents to detect changes in DNA copy number in both hormonepositive and
 hormone-negative patients using an improved FISH assay. In June, Exagen closed
 a Series B round of financing with investors Tullis- Dickerson & Co., vSpring
 Capital and Wasatch Venture Fund.
     "This transition reflects the success of Exagen to date," said Thomas
 Dickerson, chairman of Tullis-Dickerson & Co. and chairman of the Exagen board
 of directors. "Dr. Tuttle's extraordinary vision and determination have
 enabled the company to assemble its technology platform and to bring its
 initial products into clinical trials that enable FDA clearance. Jim
 McClintic's proven successes in growing diagnostic franchises and in
 commercializing products will ensure the company's future."
     About Exagen Diagnostics, Inc.
     As an emerging leader in the development of prognostic and predictive in
 vitro diagnostic (IVD) kits, Exagen Diagnostics is uniquely able to discover,
 validate and productize small sets of genomic markers for use in oncology,
 infectious disease and other indications. Exagen aims to commercialize IVD
 kits that can be performed by existing diagnostic laboratories and to develop
 tests that accompany the launch of new therapeutics and/or support
 pharmaceutical R&D/Phase IV. For more information, visit

SOURCE Exagen Diagnostics, Inc.